10-Q: Azenta Reports Q2 2026 Results, Faces Goodwill Impairment

Azenta, Inc. reported its Q2 2026 financial results, showing a slight revenue increase but a significant net loss driven by a $149.1 million goodwill impairment charge.

Summary

• Azenta, Inc. reported total revenue of $144.8 million for the three months ended March 31, 2026, a 1.0% increase compared to the same period last year.
• For the six months ended March 31, 2026, total revenue was $293.4 million, a 0.9% increase year-over-year.
• The company recorded a significant net loss of $160.8 million for the three months ended March 31, 2026, and $176.2 million for the six months ended March 31, 2026.
• A substantial portion of the net loss is attributed to a non-cash goodwill impairment charge of $149.1 million, impacting the Multiomics and Sample Management Solutions (SMS) segments.
• The B Medical Systems business, classified as held for sale, continues to operate under discontinued operations, with a reduced loss of $3.8 million for the quarter.
• The acquisition of UK Biocentre Limited for approximately $27.5 million was completed on March 4, 2026, strengthening the SMS segment in Europe.
• The company reported material weaknesses in its internal control over financial reporting, specifically related to cash flow statement review, account reconciliations, and expense classification.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the substantial goodwill impairment, net loss, and ongoing internal control weaknesses, despite modest revenue growth and a strong cash position.

Positives

• Total revenue increased by 1.0% for the three months ended March 31, 2026, and 0.9% for the six months ended March 31, 2026, compared to the prior year periods.
• The Sample Management Solutions (SMS) segment showed revenue growth of 1.6% for the quarter and 1.0% for the six months.
• The acquisition of UK Biocentre is expected to strengthen the company's presence and capabilities in the European life sciences market.
• The company has a strong liquidity position with $564.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
• The loss from discontinued operations for the B Medical Systems business decreased significantly to $3.8 million for the quarter compared to $27.9 million in the prior year.

Negatives

• The company reported a substantial net loss of $160.8 million for the three months and $176.2 million for the six months ended March 31, 2026.
• A significant goodwill impairment charge of $149.1 million was recorded, reflecting a decline in the fair value of the Multiomics and SMS reporting units.
• Gross margin decreased to 42.8% for the quarter and 42.9% for the six months, down from 43.8% and 45.3% respectively in the prior year.
• The Multiomics segment experienced a decline in operating margin, with adjusted operating margin decreasing to -15.8% for the quarter.
• The sale of the B Medical Systems business to Thelema S.R.L. did not close by the March 31, 2026 deadline due to financing issues, creating uncertainty.
• Material weaknesses in internal control over financial reporting were identified and remain outstanding, impacting the reliability of financial reporting.

Risks

• The failure of Thelema S.R.L. to secure financing for the acquisition of the B Medical Systems business could lead to continued operational burdens and potential impairment charges.
• Goodwill and intangible assets may become impaired if the performance of reporting units does not meet expectations or due to macroeconomic downturns.
• The company faces risks related to the integration of the newly acquired UK Biocentre and realizing expected synergies.
• The ongoing legal dispute with Edwards Vacuum LLC regarding the sale of the semiconductor cryogenics business could result in an adverse outcome.
• Material weaknesses in internal controls could lead to misstatements in financial reporting that are not prevented or detected in a timely manner.

Future Outlook

The company's outlook is impacted by the uncertainty surrounding the B Medical Systems sale and the significant goodwill impairment. Management believes its current cash position is sufficient for at least one year, but acknowledges the difficulty in predicting longer-term liquidity requirements due to the global economic environment. Future performance will depend on the successful integration of UK Biocentre, continued focus on the core SMS and Multiomics segments, and remediation of internal control weaknesses.

Management Comments

• The company's performance for the three and six months ended March 31, 2026, showed revenue growth driven by both operating segments.
• The goodwill impairment charge of $149.1 million was a result of assessing events and circumstances that affected the fair value of reporting units, including a sustained decline in stock price and revised forecasts.
• The company is committed to improving its internal control over financial reporting and is taking steps to remediate identified material weaknesses.

Industry Context

StockSavvy.ai notes that Azenta's results reflect challenges common in the life sciences tools and services sector, including the impact of macroeconomic uncertainty on R&D spending and the need for strategic portfolio adjustments. The significant goodwill impairment suggests a reassessment of future growth prospects for its Multiomics and SMS segments in the current market.

Comparison to Industry Standards

• The gross margin of 42.8% for the quarter is slightly below the industry average for life sciences tools and services companies, which typically ranges from 45% to 55%.
• The significant goodwill impairment charge of $149.1 million is a substantial event, indicating a potential overvaluation of acquired assets or a significant downturn in the expected future performance of the acquired businesses compared to industry peers who may have managed integration and valuation more effectively.
• The company's revenue growth of approximately 1% is modest and lags behind the growth rates of some leading competitors in the sample management and genomic services space, which have reported higher single-digit or low double-digit growth.
• The material weaknesses in internal controls are a concern, as robust financial reporting and controls are standard expectations for publicly traded companies in this sector, especially for those with complex global operations.

Management Changes

Legal Proceedings

• The company is subject to various legal proceedings, both asserted and unasserted, arising in the ordinary course of business. As of the filing date, the company believes none of these claims will have a material adverse effect on its financial condition or results of operations.
• An ongoing indemnification dispute with the buyer of the semiconductor cryogenics business (Edwards Vacuum LLC) remains pending, with the company's motion to dismiss the lawsuit still under review.

Related Party Transactions

• The sale of the B Medical Systems business to Thelema S.R.L. is a related party transaction, as Thelema's majority owner is a current Vice President of Azenta and Chief Executive Officer of B Medical Systems.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and goodwill impairment, which could negatively affect share price.
• Employees may face uncertainty due to the ongoing B Medical Systems sale delay and the company's focus on restructuring and remediation efforts.
• Creditors are likely not significantly impacted given the company's strong cash position and lack of outstanding debt.

Next Steps

• Continue to work towards closing the sale of the B Medical Systems business.
• Implement and monitor remediation plans for material weaknesses in internal controls.
• Integrate the acquired UK Biocentre business and realize expected synergies.
• Continue to focus on revenue growth and profitability in the Sample Management Solutions and Multiomics segments.

Key Dates

Recommendation

While Azenta shows modest revenue growth and a strong cash position, the significant goodwill impairment, substantial net loss, and ongoing material weaknesses in internal controls present considerable risks. The uncertainty surrounding the B Medical Systems divestiture further complicates the outlook. A 'hold' recommendation is appropriate pending clearer resolution of these issues and demonstrated operational improvements.

Keywords

Azenta, Form 10-Q, Quarterly Report, Financial Results, Goodwill Impairment, Sample Management Solutions, Multiomics, B Medical Systems, UK Biocentre, Life Sciences